DeLucia A, Wakefield T W, Andrews P C, Nichol B J, Kadell A M, Wrobleski S K, Downing L J, Stanley J C
Jobst Research Laboratories, Department of Surgery, University of Michigan Medical Center, Ann Arbor.
J Vasc Surg. 1993 Jul;18(1):49-58; discussion 58-60. doi: 10.1067/mva.1993.42736.
The role of total cationic charge of synthetic protamine-like peptides in heparin anticoagulation reversal and accompanying adverse hemodynamic effects was studied.
Five protamine variants having specific total charges of [+8], [+16], [+18], [+20], and [+21] were synthesized by fluorenylmethoxycarbonyl procedures. Each of these lysine-containing peptides plus arginine-containing control salmine native protamine (n-protamine, [+21] charge) was studied in five dogs who received heparin 150 IU/kg intravenously followed by 1.5 mg/kg (intravenously during a 10-second period) of the synthesized peptide or control n-protamine.
Anticoagulation reversal as assessed by a number of coagulation tests was more effective with peptides of greater cationic charge. In this regard, activated clotting time reversal 3 minutes after peptide administration was 7%, [+8]; 54%, [+16]; 81%, [+18]; 92%, [+20]; 81%, [+21]; and greater than 100% [n-protamine]. Reversal of heparin anticoagulation at 3 and 30 minutes, respectively, correlated significantly (p < or = 0.05, p < or = 0.01 [see corresponding symbols within abstract]) with total cationic charge as assessed by activated clotting time (r = 0.97, 0.99 ), prothrombin time (r = 0.98, 0.87), activated partial thromboplastin time (r = 0.99, 0.78), thrombin clotting time (r = 0.84,* 0.85*), heparin anti-Xa activity (r = 0.87,* 0.85*), and heparin anti-IIa activity (r = 0.79 at 3 minutes, p = 0.06). Maximum declines in systemic mean arterial pressure (MAP) were greater with more positively charged peptides: -1 mm Hg, [+8]; -3 mm Hg, [+16]; -31 mm Hg; [+18]; -31 mm Hg, [+20]; -35 mm Hg, [+21]; and -34 mm Hg [n-protamine]. Maximum decreases in MAP, cardiac output, and systemic oxygen consumption were highly correlated (p < or = 0.05) with total cationic charge: MAP, r = 0.87; cardiac output, r = 0.87; and systemic oxygen consumption, r = 0.86. A total toxicity score, reflecting adverse hemodynamic effects, was greater with increasing charge: -1.9 +/- 1.1, [+8]; -2.7 +/- 0.8, [+16]; -6.6 +/- 3.3, [+18]; -6.1 +/- 3.5, [+20]; -6.9 +/- 3.8, [+21]; and -7.0 +/- 5.2 [n-protamine]. The correlation of mean peptide total toxicity score to total cationic charge was significant (r = 0.89, p < 0.05).
These data suggest for the first time that effective alternatives to salmine protamine for reversal of heparin anticoagulation can be synthesized. Furthermore, total cationic charge appears to be an important determinant for both anticoagulation reversal and toxicity of protamine-like peptides.
研究合成的类鱼精蛋白肽的总阳离子电荷在肝素抗凝逆转及伴随的不良血流动力学效应中的作用。
采用芴甲氧羰基方法合成了五种具有特定总电荷[+8]、[+16]、[+18]、[+20]和[+21]的鱼精蛋白变体。在五只犬中对每种含赖氨酸的肽以及含精氨酸的对照鲑精蛋白天然鱼精蛋白(n-鱼精蛋白,[+21]电荷)进行研究,这些犬先静脉注射150IU/kg肝素,随后静脉注射1.5mg/kg(在10秒内)的合成肽或对照n-鱼精蛋白。
通过多项凝血试验评估,阳离子电荷更高的肽在抗凝逆转方面更有效。在这方面,肽给药后3分钟活化凝血时间的逆转率为:[+8]为7%;[+16]为54%;[+18]为81%;[+20]为92%;[+21]为81%;n-鱼精蛋白大于100%。分别在3分钟和30分钟时肝素抗凝的逆转与通过活化凝血时间评估的总阳离子电荷显著相关(p≤0.05,p≤0.01[见摘要内相应符号])(r = 0.97,0.99)、凝血酶原时间(r = 0.98,0.87)、活化部分凝血活酶时间(r = 0.99,0.78)、凝血酶凝血时间(r = 0.84*,0.85*)、肝素抗Xa活性(r = 0.87*,0.85*)以及肝素抗IIa活性(3分钟时r = 0.79,p = 0.06)。带正电荷更多的肽使全身平均动脉压(MAP)的最大下降幅度更大:[+8]为-1mmHg;[+16]为-3mmHg;[+18]为-31mmHg;[+20]为-31mmHg;[+21]为-35mmHg;n-鱼精蛋白为-34mmHg。MAP、心输出量和全身氧消耗的最大降幅与总阳离子电荷高度相关(p≤0.05):MAP,r = 0.87;心输出量,r = 0.87;全身氧消耗,r = 0.86。反映不良血流动力学效应的总毒性评分随电荷增加而升高:[+8]为-1.9±1.1;[+16]为-2.7±0.8;[+18]为-6.6±3.3;[+20]为-6.1±3.5;[+21]为-6.9±3.8;n-鱼精蛋白为-7.0±5.2。平均肽总毒性评分与总阳离子电荷的相关性显著(r = 0.89,p<0.05)。
这些数据首次表明,可以合成用于逆转肝素抗凝的鲑精蛋白的有效替代物。此外,总阳离子电荷似乎是类鱼精蛋白肽抗凝逆转和毒性的重要决定因素。